San Francisco-based private financial group engaged by biotech developer as lead placement agent for capital raise.
KNOXVILLE, TN - 01/22/2019 — US Capital Global Securities, an affiliate of US Capital Global, is offering to accredited investors a $5 million preferred equity investment in the privately held medical device company, EDP Biotech Corporation (“EDP Biotech”).
EDP Biotech’s first commercial product is ColoPlex™, a new biomarker assay to be used in the early detection of colorectal cancer. EDP Biotech performs research and develops commercialized, in vitro immunodiagnostic products aimed at identifying the early stages of biological changes in humans and animals.
Headquartered in San Francisco, US Capital Global is a full-service private financial group with teams that have an established track record in investment banking and capital raise services. Its registered broker-dealer affiliate, US Capital Global Securities, LLC, is acting as the exclusive placement agent for the equity raise for EDP Biotech.
“We are excited to have US Capital Global Securities’ experienced team assist us in raising this Series A round of funding, which will enable EDP Biotech to launch ColoPlex™ into the European market,” said Eric Mayer, CEO at EDP Biotech. “US Capital Global’s support and expertise enables EDP Biotech to enhance its platform, finalize its product, and go to market.”
“It has been a pleasure serving EDP Biotech as its lead financial advisor,” said Charles Towle, CEO at US Capital Global Securities. “Our shared enthusiasm for EDP Biotech’s unique product was a key determinant in accepting this engagement. With US Capital Global Securities’ financial advisory and capital raise services, EDP Biotech is in a strong position to advance its strategic market expansion into the rapidly growing medical device sector. The opportunity to participate in this $5 million preferred equity investment is now open to eligible investors.”
About EDP Biotech Corporation
EDP Biotech Corporation (“EDP Biotech”) is a privately held, ISO 13485:2016 certified in vitro diagnostics developer and manufacturer. Incorporated in 2005, the company focuses on the development and commercialization of simple and cost-effective diagnostics that detect disease early in humans and animals. Having spent many years researching the colon cancer testing market, EDP Biotech was able to identify market changes and develop its first commercial product, ColoPlex™, a new biomarker assay to be used in the early detection of colorectal cancer.
About US Capital Global
US Capital Global Securities, LLC is the FINRA-licensed broker dealer division of US Capital Global that acts as placement agent for growth-stage companies, projects, and investment funds. Since 1998, the US Capital Global team has been committed to providing small and lower middle market businesses and investors with sophisticated debt, equity, and investment opportunities usually available only to larger middle market companies and institutional investors. US Capital Global manages direct investment funds and provides wealth management and capital raise services. To learn more about US Capital Global Securities or this investment opportunity, email Charles Towle, CEO, at email@example.com or call +1 415-889-1010.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the EDP's expectations with regard to the future impact on the EDP's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward- looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
EDP Biotech Corporation
Early Detection Products
6701 Baum Drive Suite 110
Knoxville, TN 37919
Media Contacts:Company Name: Spur Public Relations